

Algeron Pharmaceuticals (CSE: AGN)'s soon to launch clinical trial of DMT for stroke will be the first of a kind. As Forbes talked about in today's article, DMT is a fast acting and short duration drug. AGN's trial is extremely significant because the primary focus of AGN's Phase 1 DMT study is to investigate prolonged intravenous infusion of DMT, for durations which have never been clinically studied. The resulting data generated will help AGN plan both its Phase 2 acute stroke and rehabilitation studies more effectively.

The purpose of AGN's study is to identify the safety, tolerability, and pharmacokinetics of DMT when administered as an intravenous bolus followed by prolonged infusion. The first part of AGN's study will use a single-escalating dose design while the second part will test the effects of repeated administrations of the highest safe dose. There will be up to 60 healthy volunteers enrolled across the two parts of the study which will include both psychedelic experienced and psychedelic naïve patients.

Past performance is not an indicator of future returns. NIA is not an investment advisor and does not provide investment advice. Always do your own research and make your own investment decisions. This message is not a solicitation or recommendation to buy, sell, or hold securities. NIA has received compensation from AGN of US\$100,000 cash for a twelve-month marketing contract. This message is meant for informational and educational purposes only and does not provide investment advice.

[Unsubscribe](#)

National Inflation Association
96 Linwood Plaza #172
Fort Lee, NJ 07024
